LifeStance Health Group (NASDAQ:LFST - Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter. LifeStance Health Group has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Investors interested in registering for the company's conference call can do so using this link.
LifeStance Health Group (NASDAQ:LFST - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. The firm had revenue of $312.30 million for the quarter, compared to the consensus estimate of $305.85 million. LifeStance Health Group had a negative return on equity of 10.51% and a negative net margin of 13.05%. The company's revenue for the quarter was up 20.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.13) earnings per share. On average, analysts expect LifeStance Health Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
LifeStance Health Group Price Performance
LifeStance Health Group stock traded down $0.10 during midday trading on Thursday, reaching $6.71. The company's stock had a trading volume of 995,021 shares, compared to its average volume of 1,474,969. The firm has a market capitalization of $2.57 billion, a PE ratio of -16.61 and a beta of 1.24. LifeStance Health Group has a fifty-two week low of $4.64 and a fifty-two week high of $9.20. The stock's 50 day simple moving average is $6.81 and its 200 day simple moving average is $6.15. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.22 and a current ratio of 1.22.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on the stock. UBS Group reduced their price target on shares of LifeStance Health Group from $9.00 to $7.50 and set a "neutral" rating for the company in a research report on Thursday, August 15th. Barclays cut their price target on LifeStance Health Group from $8.00 to $6.00 and set an "underweight" rating for the company in a research note on Friday, August 9th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, LifeStance Health Group presently has a consensus rating of "Hold" and an average price target of $8.25.
Read Our Latest Stock Analysis on LifeStance Health Group
Insider Buying and Selling
In other news, insider Ann Varanakis sold 5,269 shares of LifeStance Health Group stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $6.28, for a total value of $33,089.32. Following the completion of the sale, the insider now owns 263,007 shares of the company's stock, valued at $1,651,683.96. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 6.60% of the stock is owned by company insiders.
LifeStance Health Group Company Profile
(
Get Free Report)
LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.
See Also
Before you consider LifeStance Health Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeStance Health Group wasn't on the list.
While LifeStance Health Group currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
